Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) uses the angiotensin‑converting enzyme 2 (ACE2) receptor to enter host cells. Genetic variation in the ACE2 gene may influence host inflammatory responses and clinical outcomes in COVID‑19. Concurrently, tuberculosis (TB) can increase ACE2 expression through interferon‑driven pathways. The study reported here set out to examine whether specific ACE2 single‑nucleotide polymorphisms (SNPs), notably rs2285666 and rs147311723, are associated with susceptibility, inflammatory response, and biochemical markers in SARS‑CoV‑2 and Mycobacterium tuberculosis co‑infection.
This work is a retrospective cross‑sectional study of 120 symptomatic individuals recruited from four hospitals in Yaounde, Cameroon, between September 2020 and December 2023. Participants were grouped as COVID‑19 alone, TB alone, TB/COVID‑19 co‑infection, or infection‑negative controls. SARS‑CoV‑2 infection was confirmed by RT‑PCR and TB was confirmed using standard microbiological methods. The authors report that ethical approval was obtained from the regional ethical committee of research for human health in Yaoundé, Cameroon.
Serum biochemical markers and a panel of cytokines were quantified for all participants. Genotyping of selected ACE2 polymorphisms was performed using TaqMan assays. The manuscript lists multiple ACE2 SNPs examined; results reported in the abstract highlight associations for rs6632677, rs147311723, rs4646140, rs2285666, and rs4646142. All data generated in this work are stated to be contained within the manuscript.
Statistical analyses identified a significant relationship between ACE2 expression and several inflammatory and biochemical markers, with rs147311723 showing particularly notable associations. Multiple ACE2 variants—including rs6632677, rs147311723, rs4646140, rs2285666, and rs4646142—were significantly associated with elevated pro‑inflammatory cytokine levels. The analyses indicate that ACE2 genetic variability correlates with modulation of the host inflammatory response in the context of SARS‑CoV‑2 and TB infections.
Selected biochemical parameters showed suggestive associations with particular ACE2 variants, potentially indicating organ‑specific involvement linked to genotype. Reported associations and p values from the abstract include:
These p values are close to conventional significance thresholds and are reported in the abstract as suggestive rather than definitive evidence of organ dysfunction tied to ACE2 variants.
Principal component analysis (PCA) was used to explore combined immunological and metabolic features across patient groups. PCA identified distinct immunometabolic profiles, with co‑infected individuals showing heightened inflammatory and metabolic perturbations compared with single‑infection or control groups. This multivariate approach supports the concept that host genetic variation in ACE2 may shape complex immunometabolic responses during co‑infection.
The authors conclude that ACE2 genetic variability is associated with modulation of inflammatory responses and may contribute to organ‑specific dysfunction in COVID‑19 and TB, particularly noting the clinical relevance of rs2285666 and rs147311723. They emphasize the need for larger studies in diverse populations to validate these associations. Important caveats include that this report is a preprint and has not been peer reviewed; the study is retrospective and of moderate size (n = 120), and the abstract reports some associations with p values near but not below standard thresholds for significance. The manuscript states that all study data are contained in the article and that ethical oversight and participant consent were obtained.
Clinicians and researchers should interpret these findings as preliminary. The reported associations link ACE2 polymorphisms to inflammatory marker elevations and suggest potential renal and hepatic signals, but confirmation in larger, prospective, and ethnically diverse cohorts will be necessary before translating these observations into clinical guidance.